Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Revenue (2017 - 2026)

Akebia Therapeutics has reported Revenue over the past 9 years, most recently at $57.6 million for Q4 2025.

  • Quarterly Revenue rose 23.93% to $57.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $236.2 million through Dec 2025, up 47.46% year-over-year, with the annual reading at $236.2 million for FY2025, 47.46% up from the prior year.
  • Revenue was $57.6 million for Q4 2025 at Akebia Therapeutics, down from $58.8 million in the prior quarter.
  • Over five years, Revenue peaked at $126.4 million in Q2 2022 and troughed at -$152.1 million in Q4 2021.
  • The 5-year median for Revenue is $50.5 million (2021), against an average of $43.3 million.
  • The largest YoY upside for Revenue was 225.04% in 2021 against a maximum downside of 539.47% in 2021.
  • A 5-year view of Revenue shows it stood at -$152.1 million in 2021, then skyrocketed by 136.68% to $55.8 million in 2022, then grew by 0.74% to $56.2 million in 2023, then decreased by 17.26% to $46.5 million in 2024, then grew by 23.93% to $57.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Revenue are $57.6 million (Q4 2025), $58.8 million (Q3 2025), and $62.5 million (Q2 2025).